|
the current phase 3 tdm1 trial is head to head against tykerb/xeloda
and the phase 2 trial is tdm1 against taxotere in first line setting.
currently there are no trials for patients with progression following tykerb/xeloda.
but dna is starting a new trial of tdm1 and pertuzumab in may..
|